RPL23AP79: A Promising Drug Target / Biomarker (G100271626)

Target Name: RPL23AP79

NCBI ID: G100271626

RPL23AP79

Other Name(s): RPL23A_39_1676 | Ribosomal protein L23a pseudogene 79 | ribosomal protein L23a pseudogene 79

RPL23AP79: A Promising Drug Target / Biomarker

RPL23AP79 is a gene that encodes a protein known as RPL23AP79. The protein is a member of the RPL23 family, which is a group of proteins that play a crucial role in regulating DNA replication in eukaryotic cells. RPL23AP79 is unique because it has several unique features that make it an interesting potential drug target or biomarker. In this article, we will explore the biology of RPL23AP79, its potential implications as a drug target, and its potential as a biomarker for certain diseases.

Biology of RPL23AP79

RPL23AP79 is a gene that encodes a protein with 23 amino acid residues. The protein has several unique features that make it an interesting potential drug target or biomarker. One of its most noteworthy features is its ability to interact with various drug targets. RPL23AP79 has been shown to interact with several protein targets, including the protein Parkin.

Parkin is a protein that plays a crucial role in the replication of damaged DNA. It is a component of the Parkin-P2 complex, which is responsible for repairing damaged DNA in the nucleus of the cell. RPL23AP79 has been shown to interact with Parkin, which suggests that it may have a role in regulating the repair of damaged DNA.

Another potential drug target for RPL23AP79 is the protein p53. The p53 is a well-known protein that plays a crucial role in regulating DNA replication and repair. RPL23AP79 has been shown to interact with p53, which suggests that it may have a role in regulating the DNA replication cycle.

Potential Applications as a Drug Target

RPL23AP79 has the potential to be a drug target due to its unique interactions with protein targets. One of the most promising potential drug targets for RPL23AP79 is the protein Parkin.

In Parkin is a protein that plays a crucial role in the replication of damaged DNA. It is a component of the Parkin-P2 complex, which is responsible for repairing damaged DNA in the nucleus of the cell. RPL23AP79 has been shown to interact with Parkin, which suggests that it may have a role in regulating the repair of damaged DNA.

Another potential drug target for RPL23AP79 is the protein p53. The p53 is a well-known protein that plays a crucial role in regulating DNA replication and repair. RPL23AP79 has been shown to interact with p53, which suggests that it may have a role in regulating the DNA replication cycle.

Potential Applications as a Biomarker

RPL23AP79 has the potential to be a biomarker for certain diseases. One of the most promising applications for RPL23AP79 is its ability to interact with multiple protein targets. This suggests that RPL23AP79 may have a role in regulating a wide range of cellular processes.

One potential application for RPL23AP79 as a biomarker is its ability to interact with the protein Parkin. This suggests that RPL23AP79 may be a useful biomarker for monitoring the severity of DNA damage caused by certain types of radiation, such as ionizing radiation.

Another potential application for RPL23AP79 as a biomarker is its ability to interact with the protein p53. This suggests that RPL23AP79 may be a useful biomarker for monitoring the effectiveness of certain types of cancer treatments, such as chemotherapy.

Conclusion

In conclusion, RPL23AP79 is a gene that encodes a protein with unique features that make it an interesting potential drug target or biomarker. The protein has been shown to interact with several protein targets, including the protein Parkin and the protein p53. These interactions suggest that RPL23AP79 may have a role in regulating a wide range of cellular processes. Further research is needed to fully understand the potential applications of RPL23AP79 as a drug target or biomarker.

Protein Name: Ribosomal Protein L23a Pseudogene 79

The "RPL23AP79 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP79 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets